A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)

Conditions

• Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Deucravacitinib — DRUG
  As prescribed by treating clinician

Study Details

The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis

Key Dates

Start date

Jan 29, 2025

Status verified

May 2026

Primary completion

Apr 30, 2028

Completion

Apr 30, 2028

Study Design

Enrollment

350 participants (estimated)

Arms

• Arm: Participants that have initiated deucravacitinib treatment

Primary Outcome Measure

Physician's Global Assessment (PGA) 0/1 response [ Time Frame: Baseline and at months 4, 12, 18 (optional), and 24 ]

Central Contacts

• BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
  855-907-3286
  [email protected]
• First line of the email MUST contain NCT # and Site #.

Related Studies

• Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
  Recruiting · University of California, San Diego · La Jolla, California
• Regulation of Inflammatory Genes in Psoriasis
  Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
• LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
  Enrolling By Invitation · Bausch Health Americas, Inc. · Bridgewater, New Jersey
• An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
  Recruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey